You are here:
Forthcoming Submission: crizotinib (Xalkori)
Indication: First line treatment of adults with anaplastic lymphoma kinase positive advanced non small cell lung cancer.
|Drug Name:||crizotinib (Xalkori)|
|Drug Manufacturer:||Pfizer Ltd|
|Sub Category:||8.1 Cytotoxic drugs|
|Submission type:||Full submission|
|SMC Meeting Date:||TBC|